The Oncology Institute Achieves $1.1 Million in Medicare Savings in CMS Enhancing Oncology Model Performance Period 2 through its California Professional Corporation
The Oncology Institute (NASDAQ: TOI) has reported significant Medicare savings of $1.1 million during Performance Period 2 of the CMS Enhancing Oncology Model (EOM) through its California professional corporation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
The Oncology Institute (NASDAQ: TOI) has reported significant Medicare savings of $1.1 million during Performance Period 2 of the CMS Enhancing Oncology Model (EOM) through its California professional corporation. The company achieved savings of over $3,500 per patient episode and earned maximum scores for reducing avoidable emergency department visits and hospital admissions.
The success was attributed to TOI's High Value Cancer Care program, featuring Health Care Coaches and 24/7 symptom management support. This performance builds on TOI's previous achievements in CMS's Oncology Care Model, where it exceeded quality standards and generated multi-million-dollar Medicare savings.
Positive
- Achieved $1.1 million in Medicare savings through EOM program
- Earned maximum score on avoidable emergency department visits and hospital admissions
- Generated savings of over $3,500 per patient episode
- Successfully implemented 24/7 symptom management support system
Negative
- None.
Details
News Market Reaction – TOI
On Sep 22, the day this news came out, TOI closed 9.62% above the previous close.
Data tracked by StockTitan Argus for the Sep 22 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Practice earns maximum quality points on avoidable ED visits and admissions, saving more than
CERRITOS, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute of Hope and Innovation (NASDAQ: TOI), a leading value-based oncology practice, achieved
EOM is a voluntary total-cost-of-care model created by the CMS Innovation Center to advance high-quality, person-centered, and equitable cancer care for Medicare Fee-for-Service beneficiaries.
“These results again prove that our proactive navigation and real-time symptom management reduce unnecessary hospital visits and keep patients on treatment,” said Dr. Yale D. Podnos, Chief Medical Officer and President of Practice. “Patients across all our markets have access to these proven best practices to ensure each patient receives the right care at the right time.”
“This performance reinforces TOI’s leadership in value-based oncology,” said Dan Virnich, Chief Executive Officer. “By delivering measurable savings while improving quality, we continue to demonstrate that high-value cancer care is both clinically superior and financially sustainable.”
TOI’s success in EOM builds on its track record in CMS’s prior Oncology Care Model, where the organization exceeded quality standards and generated multi-million-dollar savings for Medicare.
About The Oncology Institute (www.theoncologyinstitute.com):
Founded in 2007, The Oncology Institute (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.9 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 180 employed and affiliate clinicians and over 100 clinics and affiliate locations of care across five states and growing, TOI is changing oncology for the better.
Media
The Oncology Institute, Inc.
marketing@theoncologyinstitute.com
Investors
ICR Healthcare
TOI@icrhealthcare.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.